Kevin Danahy's most recent trade in Pulse Biosciences Inc was a trade of 5,000 Common Stock done at an average price of $1.5 . Disclosure was reported to the exchange on Feb. 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 18 Feb 2026 | 5,000 | 48,298 (0%) | 0% | 1.5 | 7,650 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 5,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 23.64 per share. | 18 Feb 2026 | 5,000 | 43,298 (0%) | 0% | 23.6 | 118,200 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 20,000 | 305,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 20,000 | 325,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 12 Feb 2026 | 20,000 | 63,298 (0%) | 0% | 1.5 | 30,600 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 23.37 per share. | 12 Feb 2026 | 20,000 | 43,298 (0%) | 0% | 23.4 | 467,400 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 12 Feb 2026 | 20,000 | 63,298 (0%) | 0% | 1.5 | 30,600 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 12 Feb 2026 | 20,000 | 43,298 (0%) | 0% | 23.5 | 470,600 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 12 Feb 2026 | 20,000 | 63,298 (0%) | 0% | 1.5 | 30,600 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 23.63 per share. | 12 Feb 2026 | 20,000 | 43,298 (0%) | 0% | 23.6 | 472,600 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 20,000 | 345,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 20,000 | 365,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 20,000 | 405,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 20,000 | 385,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 09 Feb 2026 | 20,000 | 63,298 (0%) | 0% | 1.5 | 30,600 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 21.45 per share. | 09 Feb 2026 | 20,000 | 43,298 (0%) | 0% | 21.5 | 429,000 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 09 Feb 2026 | 20,000 | 63,298 (0%) | 0% | 1.5 | 30,600 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 23.52 per share. | 09 Feb 2026 | 20,000 | 43,298 (0%) | 0% | 23.5 | 470,400 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 09 Feb 2026 | 20,000 | 63,298 (0%) | 0% | 1.5 | 30,600 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.20 per share. | 09 Feb 2026 | 20,000 | 43,298 (0%) | 0% | 25.2 | 504,000 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2025 | 4,600 | 425,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.53 per share. | 02 Oct 2025 | 4,600 | 43,298 (0%) | 0% | 18.5 | 85,238 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 02 Oct 2025 | 4,600 | 47,898 (0%) | 0% | 1.5 | 7,038 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.49 per share. | 18 Sep 2025 | 20,000 | 43,298 (0%) | 0% | 18.5 | 369,800 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 18 Sep 2025 | 20,000 | 63,298 (0%) | 0% | 1.5 | 30,600 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2025 | 20,000 | 430,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.53 per share. | 18 Sep 2025 | 400 | 43,698 (0%) | 0% | 1.5 | 612 | Common Stock |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2025 | 400 | 429,600 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin P. Danahy | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.48 per share. | 18 Sep 2025 | 400 | 43,298 (0%) | 0% | 18.5 | 7,392 | Common Stock |
| Pulse Biosciences Inc | Kevin Danahy | Chief Commercial Officer | 03 Jul 2024 | 650 | 36,537 (0%) | 0% | - | Common Stock | ||
| Pulse Biosciences Inc | Kevin Danahy | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 03 Jul 2024 | 325 | 325 | - | - | Warrant (right to buy) | |
| Pulse Biosciences Inc | Kevin Danahy | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 03 Jul 2024 | 325 | 325 | - | - | Warrant (right to buy) | |
| Pulse Biosciences Inc | Kevin Danahy | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2023 | 500,000 | 500,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin Danahy | Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.30 per share. | 30 Sep 2022 | 6,500 | 6,500 (0%) | 0% | 2.3 | 14,950 | Common Stock |
| Pulse Biosciences Inc | Kevin Danahy | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2022 | 450,000 | 450,000 | - | - | Stock Option (right to buy) | |
| Pulse Biosciences Inc | Kevin Danahy | Chief Commercial Office | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 300,000 | 300,000 | - | - | Stock Option (right to buy) |